A Single-Arm, Open, Phase Ib Study Evaluating the Safety, Preliminary Efficacy of AL8326 in the Treatment of Non-Small Cell Lung Cancer
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs AL-8326 (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Advenchen Laboratories
- 03 Feb 2025 New trial record